Around 80% of the world’s population carries BK polyomavirus in a latent state. In immunocompromised patients — kidney transplant recipients above all — reactivation can lead to a severe nephropathy. This guide covers the reference diagnostic methods, the thresholds that matter, and where rapid testing fits.
Understanding BK virus
BK polyomavirus (BKPyV) is a non-enveloped human polyomavirus with a circular double-stranded DNA genome, first described in 1971. It belongs to the Polyomaviridae family and shows particular tropism for renal tubular cells and the urothelium. Primary infection usually occurs in childhood, by the respiratory or faecal-oral route, and is almost always entirely asymptomatic.
After primary infection the virus persists for life in a latent state, mainly in the epithelial cells of the urinary tract. In an immunocompetent person the immune system keeps it in check. It is when that immune surveillance is compromised — notably by the immunosuppressive therapy prescribed after transplantation — that BK virus can reactivate and cause severe complications.
Worth knowing. BK virus seroprevalence reaches 91% in children aged five to nine. Nearly all adults carry the virus, which is why post-transplant screening is indispensable rather than optional.
Who needs screening
Reactivation concerns two main groups of transplant recipients, with clinical manifestations that differ substantially.
| Population | Manifestation | Reported frequency |
|---|---|---|
| Kidney transplant recipients | BK virus-associated nephropathy (BKVAN) | 3–10% |
| Haematopoietic stem cell transplant recipients | Haemorrhagic cystitis | 5–15% |
In kidney transplant recipients, BKVAN typically appears between the ninth and twelfth month after transplantation. Excess immunosuppression is the principal risk factor, compounded by recipient age, male sex, previous rejection episodes and the degree of HLA mismatch. Historical series, before systematic screening protocols, reported graft loss in a majority of BKVAN cases — which is precisely why early detection became standard practice.
In stem cell transplant recipients, reactivation presents instead as haemorrhagic cystitis, typically within two months of allogeneic transplantation. In severe cases, haematuria can produce clots, urinary obstruction and even acute kidney injury. This second indication is covered in detail on our page on BK virus haemorrhagic cystitis.
Detection methods
Diagnosis rests on a set of complementary techniques, chosen according to clinical context, the speed required and the infrastructure available.
Quantitative PCR
The reference method, quantifying viral DNA in urine (viruria) and plasma (viremia). A plasma load above 10,000 copies/mL — or 10,000 IU/mL against the WHO international standard — is strongly associated with the risk of nephropathy and generally triggers intervention.
Urine cytology
Detection of decoy cells, recognisable by a rounded nucleus with ground-glass chromatin. Reported sensitivity of 99% and specificity of 95% for BKVAN.
Renal biopsy
Histological examination of the graft with anti-SV40 immunohistochemistry. This gives diagnostic certainty for BKVAN, but it is invasive and requires histopathological expertise.
Rapid antigen testing
A lateral flow immunoassay detecting BKPyV directly in urine. Rapid, simple and accessible, it suits frequent monitoring. Published analytical and clinical data for this approach are on the UriFastBK data page.
Urine or plasma PCR: how to choose
Viruria generally precedes viremia by several weeks. Urine PCR offers higher sensitivity and therefore earlier detection of reactivation, but plasma PCR is regarded as the more predictive marker of progression to nephropathy. The trade-off between the two — and why it matters for screening strategy — is examined on our page on viruria versus viremia.
Recommended monitoring schedule
Guidelines from the American Society of Transplantation and European transplantation societies define a specific post-transplant surveillance calendar.
| Period | Recommendation |
|---|---|
| Months 1 to 9 | Monthly quantitative plasma PCR. This is the window of maximum reactivation risk, given the intensity of immunosuppression. |
| Months 9 to 24 | Quarterly plasma PCR. Vigilance remains warranted; BKVAN can appear late. |
| If viremia is detected | Intensified surveillance every two weeks, reduction of immunosuppression, and assessment of graft function by biopsy where needed. |
| Long-term follow-up | In any unexplained graft dysfunction, test for BK virus even beyond two years. A single negative result does not exclude infection. |
Conventional PCR follow-up requires specialised laboratory infrastructure, and turnaround times can delay management. That constraint is what makes accessible, repeatable testing worth pursuing — not to replace PCR, but to make screening more frequent than laboratory capacity alone would allow.
Managing a confirmed infection
With no specific approved antiviral against BK virus, therapeutic strategy rests principally on modulating immunosuppression. The aim is to restore the immune system’s capacity to control viral replication while maintaining enough protection against graft rejection — a delicate balance requiring considerable clinical judgement.
Several approaches exist: lowering immunosuppressant doses, withdrawing a specific agent such as mycophenolate, or switching regimen. Low-dose cidofovir has been used in some cases with variable results, despite its known nephrotoxicity. Techniques such as ELISPOT allow assessment of the BK-specific immune response and may in future guide individualised treatment.
It is precisely this absence of specific treatment that makes early detection so valuable. The earlier infection is found, the greater the chance of controlling replication through a simple adjustment of immunosuppression, without heavier intervention and without risking the graft.
Frequently asked questions
What is BK virus?
A human DNA polyomavirus described in 1971. It infects around 80% of the population during childhood and persists latently in renal cells and the urothelium. It reactivates mainly in immunocompromised patients, particularly after kidney or bone marrow transplantation.
How is BK virus infection detected?
Through complementary methods: quantitative PCR on urine and plasma, urine cytology looking for decoy cells, renal biopsy with SV40 immunohistochemistry, and rapid antigen tests. Quantitative PCR remains the reference for measuring viral load.
Who should be screened?
Principally kidney transplant recipients, with a 3 to 10% risk of BKVAN, and stem cell transplant recipients, with a 5 to 15% risk of haemorrhagic cystitis. Regular follow-up is recommended by international transplantation societies.
How often should BK virus be monitored after transplantation?
International guidelines recommend monthly PCR for the first nine months after transplantation, then every three months to the end of the second year. If viremia is detected, monitoring should increase to every two weeks.
Is there a treatment for BK virus infection?
No specific antiviral is currently approved. Management rests on reducing immunosuppression. Several anti-VP1 monoclonal antibody programmes are in clinical development, including SPyDiag’s BKNeutrol.
What are the symptoms of reactivation?
Reactivation is often asymptomatic in its early stages, which is why systematic screening matters. When symptoms do appear they can include declining graft function with rising creatinine, haematuria, pelvic pain, or signs of haemorrhagic cystitis in stem cell recipients.
Information intended for professional and educational purposes. It does not replace medical advice or the protocols in force at your transplant centre.